Haemonetics Completes Acquisition of OpSens

December 12, 2023—Haemonetics Corporation announced it has completed its acquisition of OpSens Inc., a medical device company offering commercially and clinically validated optical technology for use primarily in interventional cardiology. On October 10, OpSens announced it had entered into a definitive arrangement agreement with Haemonetics for the acquisition.

According to Haemonetics, it acquired all outstanding shares of OpSens for Can$2.90 per share in the all-cash transaction, representing a fully diluted equity value of approximately US$255 million at the current exchange rate. In connection with the closing of the transaction, OpSens’ common shares will cease trading in the public market and will be delisted from the Toronto Stock Exchange and withdrawn from the OTCQX.

Haemonetics noted that OpSens’ core products include the SavvyWire sensor-guided three-in-one guidewire for transcatheter aortic valve replacement procedures. SavvyWire acts as a pacing and pressure-monitoring wire to advance procedural workflow. The OpSens OptoWire is a pressure guidewire that aims to improve clinical outcomes by accurately and consistently measuring fractional flow reserve and diastolic pressure ratio to aid clinicians in the diagnosis and treatment of patients with coronary artery disease. OpSens also manufactures a range of fiber optic sensor solutions used in medical devices and other critical industrial applications.

The acquisition expands Haemonetics’ hospital business unit portfolio with fiber optic sensor technology in the interventional cardiology market. The Haemonetics Vascade vascular closure portfolio, combined with extensive existing commercial and clinical infrastructure, will accelerate customer access to OpSens products, stated the company.

“Expanding our hospital portfolio with OpSens products creates exciting growth and diversification opportunities while providing immediately accretive financial benefits,” stated Chris Simon, Haemonetics President and Chief Executive Officer, in the company’s press release. “We are pleased to officially welcome OpSens to Haemonetics and look forward to driving greater access to OpSens’ essential solutions and benefits for physicians and patients throughout the world.”